


Appendix A

Claim Amendments


1. (Currently amended) A compound of formula I



in which

R1 and R2 are both hydrogen or together form an additional bond,

R3 represents a phenyl derivative of formulae (a) or (b)



wherein

R4 is 1-4C-alkoxy or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R5 is 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R6 is 1-4C-alkoxy or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R7 is 1-4C-alkyl and

R8 is hydrogen or 1-4C-alkyl,

or wherein

R7 and R8 together, and with inclusion of the two carbon atoms to which they are bonded, form a spiro-linked 5-, 6- or 7-membered hydrocarbon ring, optionally interrupted by an oxygen or sulfur atom,

R9 is $-C(O)-(CH_2)_n-R_{10}$,

wherein

R10 is pyrrolidine-2,5-dione-1-yl,


n is an integer from 1 to 4,

~~or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.~~

2. (Currently amended) A compound of formula I according to claim 1 in which

R1 and R2 are both hydrogen or together form an additional bond,

R3 represents a phenyl derivative of formulae (a) or (b)



wherein

R4 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R5 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R6 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R7 is methyl and

R8 is hydrogen,

or wherein

R7 and R8 together, and with inclusion of the two carbon atoms to which they are bonded, form a spiro-linked cyclopentane, cyclohexane, tetrahydrofurane or tetrahydropyran ring,

R9 is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{R}_{10}$,

wherein

R10 is pyrrolidine-2,5-dione-1-yl,


n is an integer from 1 to 2,

or a ~~hydrate, solvate, salt, hydrate of a salt or solvate~~
~~of a salt thereof.~~

3. (Currently amended) A compound of formula I according to claim 1 in which

R1 and R2 together form an additional bond,

R3 represents a phenyl derivative of formula (a)



wherein

R4 is 1-2C-alkoxy,

R5 is 1-2C-alkoxy,

R9 is $-C(O)-(CH_2)_n-R10$,

wherein

R10 is pyrrolidine-2,5-dione-1-yl and


n is 1,

or a ~~hydrate, solvate, salt, hydrate of a salt or solvate~~
~~of a salt thereof.~~

4. (Currently amended) A compound of formula I according to claim 1 in which

R1 and R2 together form an additional bond,

R3 represents a phenyl derivative of formula (a)



wherein

R4 is methoxy,

R5 is methoxy,

R9 is $-C(O)-(CH_2)_n-R10$,

wherein

R10 is pyrrolidine-2,5-dione-1-yl and


n is 1,

or a ~~hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.~~


5. (Currently amended) A compound of formula I according to claim 1, in which the hydrogen atoms in the positions 4a and 8a are cis-configured, or a ~~hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.~~

6. (Currently amended) A compound of formula I according to claim 1, in which the absolute configuration is S in the position 4a and R in the position 8a, or a ~~hydrate, solvate, salt, hydrate of a salt or solvate of a salt~~ thereof.

7. (Original) A compound of formula I according to claim 1 with the chemical formula



8. (Currently amended) A compound of formula I according to claim 1 with the chemical formula



or a ~~hydrate, solvate, salt, hydrate of a salt or solvate~~
~~of a salt thereof.~~

9. (Original) A compound of formula I according to claim 1 with the chemical name 1-(2-{4-[(4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2-oxo-ethyl)-pyrrolidine-2,5-dione.

10. (Currently amended) A compound of formula I according to claim 1 with the chemical name 1-(2-{4-[(4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2-oxo-ethyl)-

pyrrolidine-2,5-dione or a ~~hydrate, solvate, salt,~~
~~hydrate of a salt or solvate of a salt thereof.~~

11. (Previously presented) A process of preparing a compound comprising reacting (4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-2-piperidin-4-yl-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one hydrochloride with 1-(2-chloro-ethanoyl)-pyrrolidine-2,5-dione in the presence of a base.

12. (Previously presented) A process of preparing 1-(2-{4-[(4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2-oxo-ethyl)-pyrrolidine-2,5-dione comprising reacting (4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-2-piperidin-4-yl-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one hydrochloride with 1-(2-chloro-ethanoyl)-pyrrolidine-2,5-dione in the presence of a base.

13. (Canceled)

14. (Currently amended) A pharmaceutical composition comprising one or more compounds of formula I according

to claim 1, or a pharmaceutically acceptable ~~hydrate,~~
~~solvate, salt, hydrate of a salt or solvate of a salt~~
thereof, together with a suitable pharmaceutical
auxiliary and/or excipient.

15. - 16. (Canceled)

17. (Canceled)

18. (Currently amended) A method for treating airway disorders in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable ~~hydrate, solvate, salt, hydrate of a salt or solvate of a salt~~ thereof.

19. (Currently amended) A compound of formula I according to claim 2, in which the hydrogen atoms in the positions 4a and 8a are cis-configured, or a ~~hydrate, solvate, salt, hydrate of a salt or solvate of a salt~~ thereof.

20. (Currently amended) A compound of formula I according to claim 2, in which the absolute configuration is S in

the position 4a and R in the position 8a, or a ~~hydrate,~~
~~solvate, salt, hydrate of a salt or solvate of a salt~~
thereof.

21. (Currently amended) A compound of formula I according to claim 3, in which the hydrogen atoms in the positions 4a and 8a are cis-configured, or a ~~hydrate, solvate,~~
~~salt, hydrate of a salt or solvate of a salt~~ thereof.

22. (Currently amended) A compound of formula I according to claim 3, in which the absolute configuration is S in the position 4a and R in the position 8a, or a ~~hydrate,~~
~~solvate, salt, hydrate of a salt or solvate of a salt~~ thereof.

23. (Currently amended) A compound of formula I according to claim 4, in which the hydrogen atoms in the positions 4a and 8a are cis-configured, or a ~~hydrate, solvate,~~
~~salt, hydrate of a salt or solvate of a salt~~ thereof.

24. (Currently amended) A compound of formula I according to claim 4, in which the absolute configuration is S in the position 4a and R in the position 8a, or a ~~hydrate,~~

~~solvate, salt, hydrate of a salt or solvate of a salt~~
thereof.

25. (New) The method according to claim 18, wherein the airway disorder is selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD and allergic rhinitis.

26. (New) A method for treating dermatoses in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

27. (New) The method according to claim 26, wherein the dermatose is selected from the group consisting of psoriasis and atopic eczema.

28. (New) A pharmaceutical composition comprising the compound of claim 7 together with a suitable pharmaceutical auxiliary and/or excipient.

29. (New) A pharmaceutical composition comprising the compound of claim 8, or a pharmaceutically acceptable salt thereof, together with a suitable pharmaceutical auxiliary and/or excipient.

30. (New) A method for treating airway disorders in a patient comprising administering to said patient a therapeutically effective amount of the compound of claim 7.

31. (New) A method for treating airway disorders in a patient comprising administering to said patient a therapeutically effective amount of the compound of claim 8 or a pharmaceutically acceptable salt thereof.

32. (New) The method according to claim 30, wherein the airway disorder is selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD and allergic rhinitis.

33. (New) The method according to claim 31, wherein the airway disorder is selected from the group consisting of

bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD and allergic rhinitis.

34. (New) A method for treating dermatoses in a patient comprising administering to said patient a therapeutically effective amount of the compound of claim 7.

35. (New) A method for treating dermatoses in a patient comprising administering to said patient a therapeutically effective amount of the compound of claim 8 or a pharmaceutically acceptable salt thereof.

36. (New) The method according to claim 34, wherein the dermatose is selected from the group consisting of psoriasis and atopic eczema.

37. (New) The method according to claim 35, wherein the dermatose is selected from the group consisting of psoriasis and atopic eczema.